Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: asystematic literature review
Plain language summary (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 29, 2022 Category: Cancer & Oncology Authors: Farshid Dayyani, Teresa Macarulla, Andrew Johnson, Zev A. Wainberg Source Type: research
The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer
Chemotherapy and targeted therapies with monoclonal antibodies (mABs) have represented the backbone of solid cancers treatment from their discovery to now [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 24, 2022 Category: Cancer & Oncology Authors: Claudia von Arx, Pietro De Placido, Aldo Caltavituro, Rossana Di Rienzo, Roberto Buonaiuto, Michelino De Laurentiis, Grazia Arpino, Fabio Puglisi, Mario Giuliano, Lucia Del Mastro Source Type: research
Chemosaturation for primary and secondary liver malignancies: a comprehensive update of current evidence
Since the early 1960s, [1 –2] the technique of isolated hepatic perfusion to deliver high dose chemotherapy has raised clinical interest, but failed to gain widespread application due to overall limited clinical efficacy, significant systemic toxicity and lack of overall safety (CITATION JAMA; NEJM). [3] In 2011, however, the Hepatic CHEMOSAT Delivery System (Delcath Systems Inc., New York, NY, USA), was launched as a minimally invasive approach that facilitates percutaneous hepatic perfusion (PHP) to deliver highly concentrated chemotherapy directly to the liver, thereby “saturating” the entire organ (“chemosa tur...
Source: Cancer Treatment Reviews - December 24, 2022 Category: Cancer & Oncology Authors: Arndt Vogel, Sebastian Ochsenreither, Jonathan S. Zager, Frank Wacker, Anna Saborowski Source Type: research
Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma: What we have to overcome?
Melanoma is a highly malignant neoplasm with an immune-mediated background that controls its evolution and prognosis. Accounting for less than 5% of cutaneous malignancies, it is responsible for over 75% of skin cancer-related mortality[1]. Cutaneous melanoma bears a high tumor mutational burden (TMB) (median TMB=13.5 mutations/Mb[2]), mainly as a result of the mutagenic impact of ultraviolet radiation[3]. These nonsynonymous somatic mutations are phenotypically manifested by the expression of melanoma-associated antigens (MAAs) or neoantigens[4]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 13, 2022 Category: Cancer & Oncology Authors: Dimitrios C Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, John Haanen, Helen Gogas Source Type: research
Artificial Intelligence in Cancer Research and Precision Medicine: Applications, Limitations and Priorities to Drive Transformation in the Delivery of Equitable and Unbiased Care
Artificial intelligence (AI) has experienced explosive growth in oncology and related specialties in recent years. The improved expertise in data capture, the increased capacity for data aggregation and analytic power, along with decreasing costs of genome sequencing and related biologic “omics”, set the foundation and need for novel tools that can meaningfully process these data from multiple sources and of varying types. These advances provide value across biomedical discovery, diagnosis, prognosis, treatment, and prevention, in a multimodal fashion. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 11, 2022 Category: Cancer & Oncology Authors: Chiara Corti, Marisa Cobanaj, Edward C. Dee, Carmen Criscitiello, Sara M. Tolaney, Leo A. Celi, Giuseppe Curigliano Tags: Hot Topic Source Type: research
Low grade serous ovarian cancer – a rare disease with increasing therapeutic options
Low-grade serous ovarian cancer (LGSOC) is a rare histological subtype that is biologically distinct from high-grade serous ovarian cancer (HGSOC) and other remaining histotypes of epithelial ovarian cancers such as endometrioid, clear cell, mucinous and transitional cell [1]. Approximately 3-9% of ovarian cancers are pathologically defined as the low-grade serous type. However, retrospective analyses have indicated that LGSOC has unique pathological, epidemiological, and clinical features. Therefore, while both cancers are currently treated in a similar manner, LGSOCs should be seen as a separate disease [2]. (Source: Can...
Source: Cancer Treatment Reviews - December 10, 2022 Category: Cancer & Oncology Authors: Tibor A. Zwimpfer, Ori Tal, Franziska Geissler, Ricardo Coelho, Natalie Rimmer, Francis Jacob, Viola Heinzelmann-Schwarz Tags: Anti-tumour Treatment Source Type: research
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
Hormone receptor-positive (HoR+) breast cancer (BC) accounts for 75% of all invasive breast tumors.[1] Endocrine therapy (ET) with estrogen receptor (ER) modulators, aromatase inhibitors (AI), or ER antagonists, constitutes the backbone of treatment for HoR+/HER2-negative BC, alone or in combination with targeted therapies (i.e., CDK4/6, mTOR or PI3K inhibitors). It also represents a highly successful example of precision oncology, where treatment choices are guided by predictive biomarkers. To date, beyond HoR positivity, PIK3CA somatic mutations, HER2-low status, germline BRCA1/2, and PALB2 mutations are the only actiona...
Source: Cancer Treatment Reviews - December 9, 2022 Category: Cancer & Oncology Authors: Claudette Falato, Francesco Schettini, Tom ás Pascual, Fara Brasó-Maristany, Aleix Prat Source Type: research
Erratum to “Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis” [Cancer Treat. Rev. 110 (2022) 102463]
The publisher regrets that the incorrect information regarding the authors ’ Declarations of Competing Interests was included in the above-mentioned article. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 8, 2022 Category: Cancer & Oncology Authors: Pippa Corrie, Nicolas Meyer, Rossana Berardi, Massimo Guidoboni, Maximilian Schlueter, Spyros Kolovos, B érengère Macabeo, Jean-Baptiste Trouiller, Philippe Laramée Tags: Erratum Source Type: research
Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts
Tenosynovial giant cell tumour (TGCT), previously called pigmented villonodular tenosynovitis (PVNS) or giant cell tumour of tendon sheath, is a rare mesenchymal neoplasm arising from the synovium of joints and tendon sheaths. It is molecularly characterized by recurrent genomic aberrations often involving the colony-stimulating factor 1 gene (CSF1).[1-5] The 2020 WHO Classification of Soft Tissue and Bone Tumours defines TGCT as a locally aggressive neoplasm. [6] Sarcomatous transformation with metastatic spread is exceedingly rare. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 6, 2022 Category: Cancer & Oncology Authors: Stacchiotti Silvia, D ürr Hans Roland, Schaefer Inga-Marie, Woertler Klaus, Haas Rick, Trama Annalisa, Caraceni Augusto, Bajpai Jyoti, Baldi Giacomo Giulio, Bernthal Nicholas, Blay Jean-Yves, Boye Kjetil, Broto Javier-Martin, Chen Wei-Wu Tom, Dei Tos Pao Tags: Anti-tumour Treatment Source Type: research
Inhibiting the inhibitors: development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck
Head and neck cancer, which includes cancers of the oral cavity, larynx, nasopharynx, oropharynx and hypopharynx, is the eighth most common cancer worldwide, with 878,348 new cases and 444,347 deaths reported in 2020 [1]. In Europe, 158,581 cases and 69,328 deaths were reported in 2020, and 24,093 cases and 8,240 deaths were reported in Japan [2]. In the US, it is estimated there will be 66,470 new cases and 15,050 deaths in 2022 [3,4]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 30, 2022 Category: Cancer & Oncology Authors: Robert L. Ferris, Kevin Harrington, Jonathan D. Schoenfeld, Makoto Tahara, Christina Esdar, Satu Salmio, Andreas Schroeder, Jean Bourhis Source Type: research
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives
Radical surgery with total mesorectal excision (TME) is considered standard treatment for early rectal cancer (T1-2N0) and is an important part of multimodal therapy, including preoperative chemoradiation (CRT) alone or total neoadjuvant treatment (TNT) followed by radical surgery, in locally advanced disease (cT3/4 and/or N+). However, elderly and frail rectal cancer patients are often unable to undergo or recover from major surgical interventions, combined CRT or TNT with multi-agent chemotherapy. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 27, 2022 Category: Cancer & Oncology Authors: Emmanouil Fokas, Robert Glynne-Jones, Maximillian Fleischmann, Pompiliu Piso, Nikolaos Tselis, Michael Ghadimi, Ralf-Dieter Hofheinz, Claus R ödel Source Type: research
Targeting NaPi2b in ovarian cancer
NaPi2b (encoded by SLC34A2) is one of three members of the SLC34 family of type-2 sodium-dependent phosphate transporters. The SLC34 family, including NaPi2a (SLC34A1), NaPi2b, and NaPi2c (SLC34A3), plays a critical role in whole-body phosphate homeostasis by transporting phosphate across epithelial membranes [1,2]. Whereas NaPi2a and NaPi2c are confined to the kidneys and regulate renal phosphate reabsorption, NaPi2b mRNA expression was identified in various tissues including lung, small intestine, salivary glands, mammary glands, liver, and kidney [3 –9]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 14, 2022 Category: Cancer & Oncology Authors: Susana Banerjee, Ronny Drapkin, Debra L. Richardson, Michael Birrer Tags: Anti-tumour Treatment Source Type: research
Anti-tumor Treatment Targeting NaPi2b in Ovarian Cancer
NaPi2b (encoded by SLC34A2) is one of three members of the SLC34 family of type-2 sodium-dependent phosphate transporters. The SLC34 family, including NaPi2a (SLC34A1), NaPi2b, and NaPi2c (SLC34A3), plays a critical role in whole-body phosphate homeostasis by transporting phosphate across epithelial membranes [1,2]. Whereas NaPi2a and NaPi2c are confined to the kidneys and regulate renal phosphate reabsorption, NaPi2b mRNA expression was identified in various tissues including lung, small intestine, salivary glands, mammary glands, liver, and kidney [3 –9]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 14, 2022 Category: Cancer & Oncology Authors: Susana Banerjee, Ronny Drapkin, Debra L. Richardson, Michael Birrer Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 13, 2022 Category: Cancer & Oncology Source Type: research
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: a systematic review
Colorectal cancer (CRC) is one of the most common and lethal cancers worldwide, representing 10.0% of new cases and 9.4% of cancer-related deaths, with a 5-year relative overall survival (OS) ranging from 68-90% in localized disease (stage I-III) to 11-14% in metastatic CRC (mCRC) [1]. According to the most updated clinical guidelines, the main treatment options in the upfront setting for mCRC patients encompass cytotoxic agents, anti-EGFR monoclonal antibodies, anti-VEGF targeting agents and immune checkpoint inhibitors based on RAS, BRAF genes and mismatch repair protein (MMR) status [2,3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 10, 2022 Category: Cancer & Oncology Authors: Caterina Vaghi, Gianluca Mauri, Alberto Giuseppe Agostara, Giorgio Patelli, Elio Gregory Pizzutilo, Yoshiaki Nakamura, Takayuki Yoshino, Salvatore Siena, Andrea Sartore-Bianchi Tags: Tumour Review Source Type: research
